ICS3 Antibody

ICAM-3-Targeting Antibodies: Research Applications

Key monoclonal antibodies (e.g., clone CBR-IC3/1) are widely used in immunological studies:

Clinical and Therapeutic Relevance

While no ICAM-3-targeting therapies are currently approved, its role in immune modulation suggests potential applications:

• Autoimmune Diseases: ICAM-3 blockade may attenuate aberrant T cell activation .

• Cancer Immunotherapy: ICAM-3 overexpression in leukemic cells correlates with immune evasion .

• Infectious Diseases: ICAM-3 interaction with DC-SIGN is exploited by pathogens like HIV for immune evasion .

Recent Advances in Antibody Engineering

Emerging platforms (e.g., DuoBody, ART-Ig) enable bispecific antibody development targeting ICAM-3 and co-receptors:

• Bispecific Constructs: Combine ICAM-3 targeting with CD3 engagement for redirected T cell cytotoxicity .

• Fc Engineering: Mutations (e.g., K409R/F405L) enhance heterodimerization efficiency for therapeutic applications .

Limitations and Future Directions

• Glycosylation Variability: Impacts antibody binding affinity across leukocyte subsets .

• Translational Barriers: Limited in vivo data on ICAM-3 blockade efficacy and safety .